ATE349511T1 - Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten - Google Patents

Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten

Info

Publication number
ATE349511T1
ATE349511T1 AT01908427T AT01908427T ATE349511T1 AT E349511 T1 ATE349511 T1 AT E349511T1 AT 01908427 T AT01908427 T AT 01908427T AT 01908427 T AT01908427 T AT 01908427T AT E349511 T1 ATE349511 T1 AT E349511T1
Authority
AT
Austria
Prior art keywords
microorganisms
obesity
prevention
treatment
diabetes mellitus
Prior art date
Application number
AT01908427T
Other languages
English (en)
Inventor
Chuckbook-Rhi
Hea-Jung Joung
Bong-Cheol Kim
Hang-Rae Kim
N Chuckbook-Rhi
Young-Bae Bang
Original Assignee
Bioneer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2000-0049805A external-priority patent/KR100404236B1/ko
Application filed by Bioneer Corp filed Critical Bioneer Corp
Application granted granted Critical
Publication of ATE349511T1 publication Critical patent/ATE349511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/02—Acetobacter
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/823—Acetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT01908427T 2000-05-17 2001-02-23 Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten ATE349511T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000026379 2000-05-17
KR10-2000-0049805A KR100404236B1 (ko) 2000-05-17 2000-08-26 비만 또는 당뇨병 치료용 미생물 및 상기 미생물을포함하는 의약 조성물

Publications (1)

Publication Number Publication Date
ATE349511T1 true ATE349511T1 (de) 2007-01-15

Family

ID=26637996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01908427T ATE349511T1 (de) 2000-05-17 2001-02-23 Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten

Country Status (8)

Country Link
US (4) US6808703B2 (de)
EP (1) EP1282687B1 (de)
JP (1) JP4580542B2 (de)
CN (1) CN1380902B (de)
AT (1) ATE349511T1 (de)
AU (1) AU3617001A (de)
DE (1) DE60125529T2 (de)
WO (1) WO2001088095A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050311A2 (en) * 2000-12-21 2002-06-27 Societe Des Produits Nestle S.A. Lactobacillus strain producing levan and its use in human or pet food products
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
DE60304723T2 (de) * 2002-09-09 2007-04-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno VERZWEIGTE ALPHA-GLUCANE FüR DAS GEWICHTSMANAGEMENT
CA2517245C (en) 2003-02-28 2009-01-20 Mcgill University Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
MX2007009659A (es) * 2005-02-11 2008-01-16 Technologie Biolactis Inc Uso de lactobacillus kefiranofaciens en la forma de un probiotico y un simbiotico.
CN101233231B (zh) * 2005-07-26 2011-06-29 内斯特克有限公司 抗肥胖剂及抗肥胖食品
SE529185C2 (sv) * 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
PL1983849T3 (pl) * 2006-01-20 2013-09-30 Innova Food Ab Kompozycja spożywcza zawierająca aminokwasy
EP1981516B1 (de) * 2006-01-27 2018-08-08 DuPont Nutrition Biosciences ApS Verwendung von mikroorganismen zur behandlung und vorbeugung von fettleibigkeit und und verwandten erkrankungen
JP5081242B2 (ja) 2006-08-04 2012-11-28 バイオニア コーポレイション 人間母乳から分離したプロバイオティック活性、及び体重増加抑制活性を有する乳酸菌
JP5089942B2 (ja) * 2006-09-04 2012-12-05 雪印メグミルク株式会社 内臓脂肪蓄積抑制剤
WO2008029505A1 (en) * 2006-09-04 2008-03-13 Snow Brand Milk Products Co., Ltd. Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor
EP2073643A2 (de) * 2006-10-18 2009-07-01 DSMIP Assets B.V. Verkapselung von hitze- und feuchtigkeitsempfindlichen substanzen
EP1987726A1 (de) * 2007-05-01 2008-11-05 Friesland Brands B.V. Wohlschmeckendes Nahrungsmittel mit Neutralisierungsmittel für Verbindungen mit Nebenwirkungen
EP2011506A1 (de) 2007-07-05 2009-01-07 Nestec S.A. Ergänzung zu einer Schwangerschaftsdiät
JP2009114163A (ja) * 2007-11-05 2009-05-28 Nippon Energy Kenkyusho:Kk 複合微生物の培養生成物を有効成分とする血糖降下剤および血糖降下機能食品
WO2009066681A1 (ja) * 2007-11-19 2009-05-28 Kaneka Corporation 乳酸菌含有製剤
EP2065048A1 (de) * 2007-11-30 2009-06-03 Institut Pasteur Verwendung eines L.-casei-Stammes zur Herstellung einer Zusammensetzung zur Mastzellenaktivierung
JP2011516402A (ja) 2008-03-07 2011-05-26 雪印乳業株式会社 アディポネクチン分泌促進及び／又は減少抑制剤
DK2100604T3 (da) 2008-03-10 2012-07-23 Nestec Sa Dicarboxylsyrer med medium kæde og deres derivater og metaboliske lidelser
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
WO2010096550A2 (en) 2009-02-18 2010-08-26 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
JP5569710B2 (ja) * 2009-02-27 2014-08-13 国立大学法人広島大学 肥満予防又は改善剤
BRPI0924418A2 (pt) * 2009-03-10 2018-10-16 Jinis Biopharmaceuticals Co. composições e métodos para a prevenção e o tratamento de obesidade e síndrome metabólica relacionada à obesidade
ES2763137T3 (es) * 2009-06-19 2020-05-27 Dupont Nutrition Biosci Aps Bifidobacterias para el tratamiento de diabetes y afecciones relacionadas
CN101703528B (zh) * 2009-11-25 2012-07-04 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用
CN102935092B (zh) * 2010-06-09 2014-03-26 景岳生物科技股份有限公司 新颖乳杆菌及其组合物和在制备改善糖尿病及其并发症药物中的应用
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
KR101234582B1 (ko) * 2011-04-22 2013-02-19 전남대학교산학협력단 알파 글루코시다제 활성 저해용 조성물
KR101228035B1 (ko) * 2011-06-29 2013-01-30 주식회사 쎌바이오텍 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물
CN102533588B (zh) * 2011-12-06 2013-12-11 光明乳业股份有限公司 一株产胞外多糖的短乳杆菌及其应用
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
JP5967527B2 (ja) * 2012-06-22 2016-08-10 国立研究開発法人産業技術総合研究所 食欲増進かつ体重増加抑制剤
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
EP3593811A1 (de) * 2012-09-20 2020-01-15 Prothera, Inc. Probiotische zusammensetzungen und verfahren zur behandlung von adipositas und erkrankungen im zusammenhang mit adipositas
AU2014254813B2 (en) 2013-04-17 2019-08-01 Suntory Holdings Limited Composition containing bacterium belonging to genus Lactobacillus
CN103275905B (zh) * 2013-05-31 2014-12-10 江南大学 具有预防糖尿病作用的鼠李糖乳杆菌ccfm0528
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
JP6989262B2 (ja) 2014-10-27 2022-01-05 アセコー インコーポレイテッド 皮下外来患者管理
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
GB2553701A (en) * 2015-03-18 2018-03-14 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of skin disorders
US20160353774A1 (en) * 2015-06-02 2016-12-08 Mead Johnson Nutrition Company Nutritional compositions comprising spore-forming probiotics
CA2993275C (en) 2015-08-20 2022-06-21 Aseko, Inc. Diabetes management therapy advisor
CN107028985A (zh) * 2016-02-04 2017-08-11 深圳华大基因研究院 厚壁菌类益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
EP3421041A4 (de) * 2016-02-24 2019-11-27 Nitto Pharmaceutical Industries, Ltd. Zusammensetzung zur prävention oder behandlung von stoffwechselerkrankungen mit leuconostoc-mesenteroides-produzierenden exopolysacchariden als wirkstoff
US10653728B2 (en) 2016-10-17 2020-05-19 New York University Probiotic compositions for improving metabolism and immunity
EP3580326A4 (de) 2017-02-10 2020-02-12 Perfect (China) Co. Ltd Neuartige probiotische bifidobakterienstämme
AU2018314228A1 (en) * 2017-08-06 2020-03-05 Second Genome, Inc. Streptococcus Australis as a biotherapeutics
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3688196A4 (de) * 2017-09-26 2021-07-14 Second Genome, Inc. Gemella sanguinis als biotherapeutika
TWI710321B (zh) * 2018-05-03 2020-11-21 綠茵生技股份有限公司 低糖蔬果酵素液之製作方法
JP7219026B2 (ja) * 2018-07-11 2023-02-07 雪印メグミルク株式会社 食後血糖値上昇抑制用組成物及びその製造方法
JP7811843B2 (ja) 2018-07-19 2026-02-06 ペンデュラム セラピューティクス， インコーポレイテッド 微生物生着のための方法および組成物
JP7267020B2 (ja) * 2019-01-24 2023-05-01 株式会社明治 血糖値上昇抑制作用を有する発酵乳
WO2020175869A2 (ko) * 2019-02-26 2020-09-03 전남대학교산학협력단 신규한 락토바실러스 사케이 cvl-001 균주 또는 이의 배양액을 포함하는 골 질환 또는 대사성 질환 개선, 예방 또는 치료용 조성물
CN110184214B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
CN110144311B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
CN111587952A (zh) * 2020-05-27 2020-08-28 佛山科学技术学院 一种降低家犬体脂沉积的益生菌添加剂
CN111661933B (zh) * 2020-06-30 2022-08-16 武汉合缘绿色生物股份有限公司 一种用于调节水体营养及预防病害的生物制剂及其制备方法
CN113512520B (zh) * 2021-04-29 2022-04-26 右江民族医学院 富铬富锌醋酸杆菌及其制备方法和应用
EP4183403A1 (de) * 2021-11-19 2023-05-24 Lietuvos Sveikatos Mokslu Universitetas Modifikation von fäkalen mikrobiota mit kapseln, die gram-positive bakterien enthalten
CN116121154B (zh) * 2023-04-10 2023-06-27 四川厌氧生物科技有限责任公司 一种乳明串珠菌及其应用
CN117925484B (zh) * 2024-03-19 2024-07-09 山东中科嘉亿生物工程有限公司 一株改善睡眠呼吸暂停的罗伊氏粘液乳杆菌jylb-101及其产品和应用
CN118374560B (zh) * 2024-06-26 2024-09-20 天津科技大学 一种发酵粘液乳杆菌胞外多糖及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0075604A1 (de) * 1981-09-24 1983-04-06 Asahi Kasei Kogyo Kabushiki Kaisha Mittel zur Senkung des Blutzuckerspiegels
US4568557A (en) * 1983-05-11 1986-02-04 Warner-Lambert Company Process for producing snack food product with high dietary fiber content
JPS615019A (ja) * 1984-06-18 1986-01-10 Nakano Vinegar Co Ltd 血糖低下剤
DK97986A (da) * 1985-03-08 1986-09-09 Takeda Chemical Industries Ltd Middel til inhibering af fordoejelse af sakkarid
US5527772A (en) * 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
JP2928335B2 (ja) * 1989-06-26 1999-08-03 株式会社ヤクルト本社 抗高血圧剤および飲食品
JP2939491B2 (ja) * 1989-12-11 1999-08-25 株式会社アドバンス 機能性食品
JPH0735339B2 (ja) * 1991-09-09 1995-04-19 雪印乳業株式会社 血清コレステロール上昇抑制剤及び飲食品
JP3187502B2 (ja) * 1992-01-09 2001-07-11 カネボウ株式会社 腸溶性造粒物
JP3202053B2 (ja) * 1992-01-09 2001-08-27 カネボウ株式会社 腸溶性造粒物
CA2127392C (en) * 1993-07-08 2008-05-27 Hideki Sunohara Process for producing capsule and capsule obtained thereby
CN1105883A (zh) * 1994-01-31 1995-08-02 财团法人京都巴斯德研究所 用于增强免疫功能的乳杆菌
JPH107577A (ja) * 1996-06-17 1998-01-13 Yakult Honsha Co Ltd 血糖降下剤
JP5108174B2 (ja) * 1998-04-01 2012-12-26 ガネデン バイオテック， インコーポレイテッド Ｂａｃｉｌｌｕｓｃｏａｇｕｌａｎｓ芽胞を用いてコレステロールを低減させるための方法、系、および組成物
EP0956867A1 (de) * 1998-05-12 1999-11-17 Franz-Peter Dr. Liebel Verwendung von Flavonoidglykosiden, Gerbstoffen und Mikroorganismen zur Therapie und Prophylaxe des Diabetes mellitus
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
US6641808B1 (en) * 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
US6464607B1 (en) * 1999-12-15 2002-10-15 The Goodyear Tire & Rubber Company Power transmission belt
US6486314B1 (en) * 2000-05-25 2002-11-26 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Glucan incorporating 4-, 6-, and 4, 6- linked anhydroglucose units
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus

Also Published As

Publication number Publication date
US20030180273A1 (en) 2003-09-25
EP1282687A1 (de) 2003-02-12
US20030180271A1 (en) 2003-09-25
US6808703B2 (en) 2004-10-26
AU3617001A (en) 2001-11-26
CN1380902B (zh) 2010-10-27
US20020037577A1 (en) 2002-03-28
DE60125529D1 (de) 2007-02-08
WO2001088095A1 (en) 2001-11-22
US20050112112A1 (en) 2005-05-26
JP2001321163A (ja) 2001-11-20
EP1282687B1 (de) 2006-12-27
JP4580542B2 (ja) 2010-11-17
CN1380902A (zh) 2002-11-20
DE60125529T2 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
DE60125529D1 (de) MIKROORGANISMEN FüR DIE BEHANDLUNG ODER VORBEUGUNG VON FETTLEIBIGKEIT UND DIABETES MELLITUS UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN
MA33046B1 (fr) Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp- iv et facultativemenet un autre agent antidiabetique et ses utilisations
ATE431816T1 (de) Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten
IL151473A0 (en) O-aryl glucoside derivatives and pharmaceutical compositons containing the same
BR0112685A (pt) Composição nutricional
MX2010001560A (es) Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv.
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
UA89791C2 (ru) Пищевая композиция, которая содержит неусваиваемые олигосахариды, для лечения или профилактики инфекций респираторного тракта
BR0114310A (pt) Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos
UA100008C2 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и фармацевтической композицией, которая их содержит
WO2006032500A3 (en) Immunogenic composition
BR0107901A (pt) Composto, composição farmacêutica, método para o trtamento de enfermidade, para o trtamento e/ou prevenção de condições mediadas por receptores nucleares, e para o tratamento e/ou prevenção de diabetes e/ou obesidade, uso de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância à gligose prejudicada, resistência à insulina ou obesidade
DE69328186D1 (de) Zusammensetzung zur behandlung der parkinson-krankheit
BR0314335A (pt) Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
AU2002351583A1 (en) Chitosan oligosaccharides and uses thereof
PT1254146E (pt) Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
BR0112919A (pt) Uso de óleos essenciais para combater infecção do trato gi por organismos semelhantes a helicobacter
WO2025024305A3 (en) Irak4 degraders and uses thereof
CA2412789A1 (en) Compositions for improving mental concentration
GB2456475A (en) Composition for the treatment of skin conditions
WO2006023342A3 (en) Synergistic conjugated linoleic acid (cla) and carnitine combination
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
BR0015102A (pt) Bactérias de ácido latico para o tratamento e/ou profilaxia de giardìase
AU4155700A (en) Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties